Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naive Patients with Chronic Hepatitis B.

ABSTRACT:

Background/aims

: Besifovir dipivoxil maleate (BSV) and tenofovir alafenamide fumarate (TAF) have been recently approved in Korea as the initial antiviral agents for chronic hepatitis B (CHB). However, the real-world outcome data for these drugs remain limited. Therefore, we conducted a noninferiority analysis using real-world data to compare the clinical outcomes of the two nucleotide analogs in treatment-naïve patients with CHB.

Methods

: We retrospectively investigated a cohort of patients with CHB who received BSV or TAF as first-line antiviral agents. The endpoints were virological response (VR) and liver-related clinical outcomes.

Results

: A total of 537 patients, consisting of 202 and 335 patients administered BSV and TAF, respectively, were followed up for 42

SUBMITTER: Kim TH 

PROVIDER: S-EPMC10938153 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature